AstraZeneca PLC (AQUISEU:AZNS) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Pascal Soriot Other companies: Agilent Technologies, Inc. (Director · Since at least May 20, 2025); Viela Bio Inc (Director · Oct 2, 2019 – Oct 2, 2019 · Past) | Executive Director and CEO · Since at least Oct 30, 2026 |
| Euan Ashley Other companies: DexCom, Inc. (Director · Since at least Oct 24, 2025) | Non-Executive Director · Since at least Nov 5, 2026 |
| Anna Manz | Non-Executive Director · Since at least Nov 5, 2026 |
| Aradhana Sarin | Executive Director and CFO · Since at least Nov 5, 2026 |
| Birgit Conix | Non-Executive Director · Since at least Nov 5, 2026 |
| David Fredrickson | Executive Vice-President, Oncology Business Unit · Since at least Nov 4, 2026 |
| Diana Layfield | Non-Executive Director · Since at least Nov 5, 2026 |
| Iskra Reic | Executive Vice-President, International · Since at least Jul 27, 2026 |
| Jeff Pott | Chief Human Resources Officer, Chief Compliance Officer and General Counsel · Since at least Nov 4, 2026 |
| Karen Knudsen | Non-Executive Director · Since at least Nov 5, 2026 |
| Mani Sharma | See remarks · Since at least Mar 18, 2026 |
| Marc Dunoyer | Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca · Since at least Oct 22, 2026 |
| Marcus Wallenberg | Non-Executive Director · Since at least Nov 5, 2026 |
| Maria Belvisi | Chief Scientific Officer · Apr 10, 2026 – Nov 5, 2026 · Past |
| Michel Demaré | Non-Executive Chair of the Board · Since at least Jul 27, 2026 |
| Pam Cheng | Executive Vice President, Global Operations, IT & Chief Sustainability Officer · Since at least Oct 30, 2026 |
| Ruud Dobber | Executive Vice-President, BioPharmaceuticals Business Unit · Since at least Sep 23, 2026 |
| Sharon Barr | Executive Vice-President, BioPharmaceuticals R&D · Since at least Sep 8, 2026 |
| Sheri McCoy | Non-Executive Director · Since at least Nov 5, 2026 |
| Susan Galbraith | Executive Vice-President, Oncology R&D · Since at least Oct 25, 2026 |
| Tony Mok | Non-Executive Director · Since at least Nov 4, 2026 |
| Wan Ling Martello | Non-Executive Director · Since at least Nov 5, 2026 |